MedTrace Logo

The Effect of Adalimumab (Humira) on Vascular Abnormalities in Rheumatoid Arthritis. A Pilot Study.

NCT01270087 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2011-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether anti-inflammatory treatment with adalimumab (Humira) reduces endothelial activation in blood vessels in patients with active rheumatoid arthritis. Markers of endothelial activation are assessed in muscle tissue before treatment and after 3 months, and related to other biomarkers and clinical outcomes.

Conditions

Interventions

DRUG

Adalimumab

40 mg IV every 14 days

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • The Swedish Research Council

    collaborator OTHER_GOV

  • The Swedish Rheumatism Ass

    collaborator OTHER

  • Crafoord Foundation

    collaborator OTHER

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Carl Turesson, MD, PhD · Department of Rheumatology, Skåne University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-02-28
Completion
2007-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01270087 on ClinicalTrials.gov